Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07549-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Fan Jia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, 150081,…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Peptides, Cyclic, Coordination Complexes, Radiopharmaceuticals. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Provincial Key Research and Development Program of Heilongjiang Province.
Abstract (Originalsprache)
OBJECTIVE: CXCR4 and integrin αvβ3 play important roles in tumor biology and are highly expressed in multiple types of tumors. This study aimed to synthesize, preclinically evaluate, and clinically validate a novel dual-targeted PET imaging probe 68Ga-pentixafor-c(RGDfK) for its potential in imaging tumors. METHODS: The effects of 68Ga-pentixafor-c(RGDfK) on cell viability, targeting specificity, and affinity were assessed in the U87MG cells. Micro-PET/CT imaging and biodistribution studies were conducted in U87MG tumor-bearing BALB/c nude mice to evaluate the probe's in vivo pharmacokinetics. A prospective analysis was conducted on patients who underwent both 68Ga-pentixafor-c(RGDfK) PET/CT and 18F-FDG PET/CT. The results obtained from the two imaging modalities were compared. RESULTS: In vitro, 68Ga-pentixafor-c(RGDfK) showed higher uptake activity, targeting specificity, and affinity in U87MG cells than 68Ga-pentixafor. In vivo, tumor uptake was higher than in normal tissues (P < 0.05), with renal excretion and low hepatobiliary excretion. Clinical results indicated that 68Ga-pentixafor-c(RGDfK) PET/CT had higher sensitivity, specificity, and accuracy in diagnosing primary and metastatic lesions compared to 18F-FDG PET/CT (93.1% vs. 74.7%, 79.2% vs. 62.5%, 90.1% vs. 72.1%, and 93.2% vs. 74.5%, 84.7% vs. 78%, 89.7% vs. 75.9%). The tumor-to-background ratio (TBR) at 120 min delayed scanning was significantly higher than at 60 min (P < 0.05). CONCLUSION: 68Ga-pentixafor-c(RGDfK) PET/CT demonstrated good safety and clinical feasibility in diagnosing tumors, particularly in differentiating benign and malignant lesions when 18F-FDG PET/CT results are uncertain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China.
- Department of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China. houdayong@hrbmu.edu.cn.
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
- Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China.
- Department of PET-CT/MRI, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, China. xuwanhai@hrbmu.edu.cn.
- Department of Urology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, 150081, Heilongjiang, China. xuwanhai@hrbmu.edu.cn.
ORCID-Profile: Kezheng Wang
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Provincial Key Research and Development Program of Heilongjiang Province
- Hong Kong Scholar Project
- Heilongjiang Provincial Natural Science Foundation of China
- Key Project of Harbin Medical University Cancer Hospital Climbing Funding
- Distinguished Young Scientist Funding of Harbin Medical University Affiliated Tumor Hospital
- Harbin Medical University Cancer Hospital Haiyan Foundation
Zitieren
APA
Jia, F., Hou, D., Zhang, H., You, H., Cheng, L., Liu, W., Zhao, Y., Yang, X., Zhou, X., Yu, M., Hu, G., Guo, C., Meng, H., Xu, W., & Wang, K. (2026). Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07549-9
Vancouver
Jia F, Hou D, Zhang H, You H, Cheng L, Liu W, et al. Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07549-9
BibTeX
@article{Jia2026,
author = {Jia, Fan and Hou, Dayong and Zhang, Han and You, Huihui and Cheng, Liang and Liu, Wei and Zhao, Yue and Yang, Xinyue and Zhou, Xinglu and Yu, Miao and Hu, Geng and Guo, Chenxu and Meng, Hongxue and Xu, Wanhai and Wang, Kezheng},
title = {Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07549-9}
}
EUVIMED